US FDA Gene Therapy Review Reorg Draws Congressional Interest
A bipartisan letter from the leaders of the House Energy and Commerce Committee’s Health Subcommittee indicates the FDA’s efforts to revamp the review structure for cell and gene therapies will be closely watched by key legislators.
